NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
SSII
SS Innovations International, Inc.
There isn't enough reported data to score SSII yet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
SSII Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
SSII's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
SSII PE Valuation
SSII has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
SSII Forward outlook
There aren't enough analyst estimates for SSII to show an outlook.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over SSII on earnings quality, reporting a profit while its opponent remains loss making.
SSII Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.06 | $0.00 |
| Q1 2026 | -$0.05 | +$0.03 |
| Q4 2025 | -$0.06 | +$0.05 |
| Q3 2025 | -$0.06 | +$0.11 |
| Q2 2025 | -$0.06 | +$0.10 |
| Q1 2025 | -$0.08 | +$0.10 |
| Q4 2024 | -$0.11 | +$0.33 |
| Q3 2024 | -$0.17 | +$0.50 |
SSII is still losing money, but far less than before: $0.06 per share over the past year, against $1.60 at its worst in late 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over SSII on profitability, with a higher operating margin.
SSII Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $13.9M | +39% |
| Q1 2026 | $11.1M | +117% |
| Q4 2025 | $14.5M | +79% |
| Q3 2025 | $12.8M | +192% |
| Q2 2025 | $10M | +122% |
| Q1 2025 | $5.1M | +41% |
| Q3 2024 | $4.4M | +101% |
| Q2 2024 | $4.5M | +138% |
SSII has the edge over NVO on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -16% | -17 points |
| Q1 2026 | -33% | +83 points |
| Q4 2025 | -5.1% | +18 points |
| Q3 2025 | -14% | +59 points |
| Q2 2025 | 1% | +92 points |
| Q1 2025 | -116% | +155 points |
| Q4 2024 | -23% | N/A |
| Q3 2024 | -73% | +12 points |
SSII's operating margin was −16% last quarter, down 17 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over SSII on cash generation, producing positive trailing cash flow while its opponent burns cash.
SSII Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$4.2M | -$465.5K |
| Q1 2026 | -$2.4M | +$4.6M |
| Q4 2025 | -$3.2M | +$152.8K |
| Q3 2025 | -$8.2M | -$7.4M |
| Q2 2025 | -$3.8M | -$634.5K |
| Q1 2025 | -$7M | -$4.2M |
| Q4 2024 | -$3.4M | +$2.4M |
| Q3 2024 | -$844K | +$4.3M |
SSII has burned cash in almost every quarter: −$18M over the past year, against −$15M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over SSII on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
SSII Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2% | +4.1M shares |
| 1 year | +3.2% | +6.6M shares |
| 3 years | +46% | +65.7M shares |
| 5 years | +9379% | +207M shares |
SSII has 209M diluted shares, up 3.2% from a year ago.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
SSII Net Leverage
SSII's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
SSII Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 21.7 | Oversold |
| Stochastic | 9.7 | Oversold |
SSII's weekly RSI is 22 (oversold) and its Stochastic is 10 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
SSII PE vs Healthcare Sector
SSII has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has stronger trend alignment. NVO is above 1 of 5 weekly averages versus SSII above 0 of 4.
SSII Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.35 | 44% below |
| 20 week MA | $3.11 | 58% below |
| 50 week MA | $4.01 | 67% below |
| 100 week MA | $5.87 | 78% below |
SSII is in a downtrend: it's below all four of its weekly moving averages, and 78% below its 100-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over SSII on returns for 2026, with the stronger performance.
SSII Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2024 | $3.75 | $8.00 | +113% |
| 2025 | $8.00 | $5.74 | -28% |
| 2026 YTD | $5.74 | $1.32 | -77% |
SSII has finished lower in one of the last two years. It's down 77% so far in 2026.